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Abstract
Background: Compared to the emerging embryonic stem cell (ESC) gene network, little is known about the dynamic gene
network that directs reprogramming in the early embryo. We hypothesized that Oct4, an ESC pluripotency regulator that is
also highly expressed at the 1- to 2-cell stages in embryos, may be a critical regulator of the earliest gene network in the
embryo.
Methodology/Principal Findings: Using antisense morpholino oligonucleotide (MO)-mediated gene knockdown, we show
that Oct4 is required for development prior to the blastocyst stage. Specifically, Oct4 has a novel and critical role in
regulating genes that encode transcriptional and post-transcriptional regulators as early as the 2-cell stage. Our data
suggest that the key function of Oct4 may be to switch the developmental program from one that is predominantly
regulated by post-transcriptional control to one that depends on the transcriptional network. Further, we propose to rank
candidate genes quantitatively based on the inter-embryo variation in their differential expression in response to Oct4
knockdown. Of over 30 genes analyzed according to this proposed paradigm, Rest and Mta2, both of which have
established pluripotency functions in ESCs, were found to be the most tightly regulated by Oct4 at the 2-cell stage.
Conclusions/Significance: We show that the Oct4-regulated gene set at the 1- to 2-cell stages of early embryo
development is large and distinct from its established network in ESCs. Further, our experimental approach can be applied
to dissect the gene regulatory network of Oct4 and other pluripotency regulators to deconstruct the dynamic
developmental program in the early embryo.
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Introduction
The early mammalian embryo, formed by the fusion of the
highly differentiated egg and sperm, undergoes dramatic repro-
gramming. Totipotency or pluripotency is presumed to be
established in blastomeres, followed by the first lineage-specific
differentiation into trophectoderm and the inner cell mass (ICM)
in the early blastocyst [1]. The developing fetus and embryonic
stem cell (ESC) lines are derived from the ICM, so understanding
early mammalian embryo development is critical to research on
human diseases, and to the generation of pluripotent ESCs for
therapeutic use [2–6]. Hence, determining the role of ESC
regulators of self-renewal and pluripotency in the context of the
early embryo may provide opportunities to better understand
embryo development and ESC biology. (For our purposes here,
the early embryo encompasses developmental stages that follow
fertilization and precede blastocyst formation.)
Reprogramming in the early embryo is concurrent with massive
degradation of maternal transcripts, and waves of embryonic
activation that occur at the 1- to 2-cell, 4- to 8-cell (hereafter,
multicell refers to stages between, but not including, 4-cell and
morula), and morula to blastocyst stages [7–9]. However, the
dynamic gene regulatory network that directs reprogramming has
remained elusive. We approached this dynamic gene network by
investigating the function of Oct4 (also known as Pou5f1). Oct4
expression is restricted to pluripotent cell types, and the level of
Oct4 protein can direct lineage-specific differentiation in ESCs
[10–13]. Despite rapid degradation of maternal Oct4 transcripts
starting at the 2-cell stage [10,12], maternal and embryonic Oct4
transcripts may transiently coexist. Consequently, Oct4 function
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by Oct4
2/2 mice (which have defective ICM expansion) [10],
conditional deletion of the maternal allele [supporting information
(SI) Fig. S1], or studies using small interfering RNA (siRNA)
[14,15]; sufficiently rapid knockdown of both maternal and
embryonic transcripts is unlikely to be possible. For example,
RNAi-mediated Oct4 knockdown resulted in development past the
multi-cell and morula stages to a blastocyst-like state comprising
giant trophoblasts and non-Oct4-expressing cells in the usual
location of the ICM [15]. However, the role of Oct4 during the
early cleavage stages, prior to the formation of the ICM, has not
been investigated.
Results
Morpholino-mediated Gene Knockdown
Here, we provide proof-of-concept of the efficiency and
specificity of MO-mediated gene knockdown in the mouse embryo
by testing the procedure on the Ccna2 gene. We then report the
novel role of Oct4 that was revealed by MO-mediated gene
knockdown. Ccna2, the gene encoding cell cycle regulator cyclin
A2, has been suggested as an important transcriptional regulator
in embryonic genome activation [16], a critical developmental
milestone at the 1- to 2-cell stages for which few clear mechanisms
or regulators have emerged. Consistent with the literature, MO-
mediated Ccna2 knockdown decreased cyclin A2 protein expres-
sion. In addition, our results showed that cyclin A2 is required for
development beyond the 2-cell stage (Fig. 1, A–G, SI Tables S1
and S2). MOs block translation of transcripts by steric hindrance
in an efficient and gene-specific manner, which has been well
established in zebrafish and other model organisms [17–20]. Most
importantly, MOs mediate rapid knockdown of transcripts
regardless of their maternal or embryonic origin, before activation
of downstream genes can provide partial ‘‘rescue’’ of the
phenotype.
Oct4 Knockdown at the 1- to 2-Cell Stages
By combining MO-mediated gene knockdown with global gene
expression profiling and single-embryo level quantitative RT-PCR
(q-PCR), we determined the influence of Oct4 on gene expression,
and analyzed the Oct4-regulated gene network in the early
embryo (Figs. 2 and 3; SI Fig. S2). Consistent with the literature
[12], we confirmed Oct4 gene expression at the 1-cell stage (SI Fig.
S3). After 1-cell embryos were microinjected with 0.6 mM Oct4-
MO, the rate of developmental arrest at the 1- to multicell stages
was dramatically higher than that observed for uninjected and
mismatch (Oct4-MM) controls (Fig. 2, A and B). Of embryos
injected with Oct4-MO that reached the multicell stage,
86.868.3% arrested and did not form morulae, compared to
10.5610.5% embryos injected with Oct4-MM (p,0.01; data not
Figure 1. Translational block of cyclin A2 by Ccna2-MO causes embryos to arrest at the 2-cell stage. (A) Ccna2 expression in 1- to 2-cell
embryos by RT-PCR. (B) Nuclear cyclin A2 localization was absent in 83.466.0% of Ccna2-MO-injected embryos but present in all uninjected embryos
and embryos injected with a mismatch control (Ccna2-MM); p,0.01). (C) ,50 kD cyclin A2 protein was not detected in Ccna2-MO-injected embryos.
(PBS, phosphate buffered saline.) (D) Ccna2-MO induced higher rates of 2-cell stage arrest compared to controls (p,0.01). (E) Only 1.861.8% of
Ccna2-MO-injected embryos reached blastocyst stage (p=0.06 compared to Ccna2-MM). (F) The rates of 2-cell stage arrest decreased with the
concentration of Ccna2-MO (p=0.05 for 0.5 mM; p=0.01 for 0.25 mM). (G) The rate of blastocyst development at were higher at 0.25 mM than at
0.75 mM (p,0.001). (All columns and error bars represent mean6s.e.m., respectively, from at least three independent sets of experiments. Scale bar
40 mm. See SI Table S1 for the targeted sequence of all MOs used, and SI Table S2 for the total number of embryos tested in each set of experiments.)
doi:10.1371/journal.pone.0004109.g001
The 2-Cell Embryo Needs Oct4
PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e4109shown). Most remarkably, none of the Oct4-MO-injected embryos
developed to blastocysts, compared to relatively high blastocyst
rates of Oct4-MM-injected and uninjected embryos (p,0.01;
Fig. 2C). In contrast to the blastocyst-like stage that results after
knock down of Oct4 with siRNA [15], embryos injected with Oct4-
MO did not undergo further development or cell division after the
multi-cell to morula stages. Further, the specificity of Oct4-MO is
supported by the direct relationship between the phenotype
severity and presumed ‘‘gene-dosage’’ as titrated by Oct4-MO
concentration (Fig. 2, D and E). Oct4 protein expression was
indeed reduced in Oct4-MO-injected embryos at the 4-cell (SI Fig.
S4) and multi-cell stages (Fig. 2F, SI Fig. S5). However, Oct4
knockdown could not be assessed by western blot (SI Fig. S6).
Injection of another MO, targeting an intron-exon boundary in
Oct4, confirmed that disruption of Oct4 function is detrimental to
development before the blastocyst stage (SI Fig. S7).
Partial Rescue and Overexpression by Microinjection of
Oct4 mRNA
The critical function of Oct4 at the 1- to 2-cell transition was
embryo-autonomous. The effects of Oct4 knockdown could not be
rescued by media conditioned by uninjected embryos or the in vivo
environment provided by transferring injected embryos to oviducts
of appropriately timed surrogate mothers (data not shown). Co-
injection of low (3.6 ng/mL) or high (36 ng/mL) concentrations of
unaltered, full-length Oct4 mRNA with 0.6 mM Oct4-MO resulted
in a decrease in the percentage of embryos arresting at the 1- to
multicell stages, compared to co-injection of control mRNA
Figure 2. Oct4 is required for early embryo development prior to formation of the blastocyst. (A) Oct4-MO-injected embryos arrested at
multicell stage, while uninjected and mismatch (Oct4-MM) controls reached blastocyst stage. (B) Oct4 knockdown induced higher arrest rates at the
1- to multicell stages; p,0.01. (C) None of the Oct4-MO-injected embryos developed to blastocysts. (D) The rates of arrest at the 1- to multicell stages
decreased with concentration of Oct4-MO (p,0.01). (E) There was a non-significant trend for higher rates of blastocyst development with decreasing
concentrations of Oct4-MO. (F) Nuclear Oct4 expression is absent in Oct4-MO-injected embryos (top panel) but present in Oct4-MM-injected embryos
and uninjected. The effect of Oct4 knockdown could not be assessed by western blot because Oct4 protein was not detectable in pooled embryos by
western blot (SI Fig. 6). (G) Compared to no coinjection or mEYFP mRNA co-injection, co-injection of 36 or 3.6 ng/mLo fOct4 mRNA resulted in partial
rescue of the Oct4-MO-induced phenotype by specifically decreasing the arrest rates at the 1- to multicell stages, which resulted in higher rates
blastocyst development (p,0.01). (H) Overexpression of Oct4 mRNA induced higher developmental arrest in a dose-dependent manner, such that
blastocyst rates are significantly lower after injection of Oct4 mRNA at 36 or 90 ng/mL, compared to overexpression of mEYFP (p,0.01). (Scale
bar=40 mm).
doi:10.1371/journal.pone.0004109.g002
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(mEYFP) (Fig. 2G). No embryos co-injected with Oct4 mRNA
arrested at the multicell stage, while 80.065.2% arrested after co-
injection of mEYFP mRNA (p,0.01; data not shown). Thus, co-
injection of Oct4 mRNA, but not control mRNA, partially rescued
the Oct4-MO-induced multicell stage arrest phenotype. The failure
to achieve full rescue of the phenotype and the lack of a difference
in developmental rates between the low and high concentrations of
Oct4 mRNA may be due to relative instability of the in vitro
transcribed Oct4 mRNA compared to Oct4-MO. Alternatively,
Oct4 overexpression may have adverse effects that challenge
attempts to rescue the Oct4 knockdown phenotype.
Hence, we next tested whether Oct4 over-expression itself would
interfere with development. Injection of 36 ng/mLa n d9 0mL/nL of
Oct4 mRNA resulted in 8 and 40 folds increase in Oct4 transcript
levels, respectively, while Oct4 protein localization remained nuclear
on immunocytochemistry (data not shown). Oct4 over-expression
indeed induced developmental arrest in a dosage-dependent manner,
while injection of comparable or greater amounts of mEYFP mRNA
interfered minimally with blastocyst development (Fig. 2H). The
‘‘gene dosage’’ effect of Oct4 RNA injection may be due to enhanced
Oct4 functions in transcriptional regulation, or Oct4 over-production
may allow non-specific promoter-binding, or extra Oct4 causes
inappropriate sequestration and subsequent inactivation of co-factors.
Collectively, these data definitively showed Oct4 expression was
required, and that its correct level was critical to early embryo
development, just as pluripotency of ESCs depends ona preciserange
of Oct4 expression levels [11,21].
Figure 3. Gene regulation by Oct4. (A) Unsupervised clustering of 3 Oct4 knockdown, 3 Ccna2 knockdown, and 6 uninjected (NI) pooled embryo
samples, and increased (red) and decreased (blue) gene expression. Scale is standard deviation. (B) Intersection of differentially expressed genes in
Oct4 and Ccna2 knockdown embryos. Numbers indicate genes, not Affymetrix probesets. (C–D) Relative expression of Oct4 knockdown by single-
embryo q-PCR for (C) overexpressed genes (p,0.05 for Hes5) and (D) downregulated genes (*p,,0.001, **p,0.05, ***p,0.1). TR translational
repression. Error bars indicate s.e.m. See SI Table S13 for a list of all the Taqman gene assays used for q-PCR experiments.
doi:10.1371/journal.pone.0004109.g003
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Knockdown
To dissect the mechanisms of Oct4 function, we compared the
global gene expression profile of Oct4 knockdown embryos to the
effects of Ccna2 knockdown and to uninjected controls at the mid-
2-cell stage. The goal was to identify differential gene expression
that occurred with the first major wave of embryonic genome
activation at the mid-2-cell stage [7,8] (SI Tables S3, S4, S5 and
S6). This time point was carefully selected to identify early genetic
changes in response to Oct4 knockdown, to precede developmental
or cell cycle arrest at the multi-cell stage. Analysis by an
unsupervised algorithm showed that the embryo samples clustered
according to the experimental conditions, which further supported
the specific and non-random effects of gene knockdown (Fig. 3A).
At an arbitrary threshold false discovery rate (FDR) of 0.05, the
Oct4-regulated gene set was more than 3 times larger, overall,
compared to the number of genes changing expression in response
to cyclin A2 knockdown (Fig. 3B). The different sizes of the under-
expressed versus over-expressed Oct4-knockdown gene sets sug-
gested that Oct4 may be predominantly activating rather than
repressing transcription (Fig. 3B). Some of the Oct4 candidate
target genes have previously been identified as putative Oct4
targets based on mESC chromatin immunoprecipitation (ChIP)
data or genomic sequence analysis of Oct4-binding sites [22] (SI
Table S7).
The list of cyclin A2-regulated genes was rich in genes encoding
factors for chromatin modification and remodelling (p=0.005),
nucleotide metabolism (p=0.01), and chromosome organization
(p=0.01; SI Tables S8, S9). Oct4-regulated genes were significantly
enriched for translation (p=1.1610
24) and RNA processing
functions (p=3.0610
25) (SI Tables S10, S11). Comparison of our
data with published Oct4-regulated networks in mouse ESCs [22]
indicated that Oct4 showed distinct and specific post-transcriptional
and translational regulatory functions mediated by its control of
genes encoding subunits in eukaryotic translation initiation factors
(Eif), including Eif3c, and Eif3b. Interestingly, these two Eif subunits
are evolutionarily conserved from yeast to human, and are amongst
the six subunits comprising the functional core of mammalian Eif3,
the largest of the Eif complexes [23].
In addition to its embryo-specific function, Oct4 also controls
the expression of Dppa5, as it does in ESCs (data not shown);
Dppa5 is an embryo-, germ cell- and ESC-specific RNA-binding
protein whose role in maternal-embryonic transition is not known
[24,25]. Piwil2 (also known as Mili), whose protein product and its
bound pi-RNAs are known for their role in regulating retro-
transposons in the fully-grown mouse oocyte [26], also showed a
trend of decreased expression upon Oct4 knockdown, although it
did not reach statistical significance. As importantly, at the 1- to 2-
cell stages, there was no evidence that the requirement of Oct4 in
controlling the expression levels of Cdx2 or Nanog [1,27–30] was
replicated in the 1- to 2-cell stages (data not shown). Although Sox2
showed a trend of being over-expressed in Oct4 knockdown, rather
than being down-regulated as in ESCs, this response did not reach
statistical significance (data not shown). Collectively, our data
indicated that Oct4 has a distinct and specific role in the maternal-
embryonic transition, in controlling genes encoding post-tran-
scriptional regulators, in addition to its conserved functions shared
amongst pluripotent cell types.
Maternal Transcript Degradation and Embryonic Genome
Activation
In order to understand the role of Oct4 in reprogramming the
early embryo, we examined its role in embryonic genome
activation and maternal transcript degradation. Overall, Oct4
regulates gene expression pertinent to basic machinery required
for the entire spectrum of gene regulation, including transcription
involving all three RNA polymerases, translation, RNA processing
such as regulation of polyadenylation, and mRNA degradation
proteins (SI Table S12). High levels of mRNA from developmental
genes, such as Six1, Nestin, and Hoxa3, indicated that Oct4 was
required for their repression, while excessive levels of maternal
transcripts that would normally be rapidly degraded, such as Zar1
and Nobox1, indicated that Oct4 knockdown interfered with the
mRNA degradation machinery. Thus, Oct4 has developmental
stage- and cell-specific functions, and has an important role in the
processes that mark maternal-embryonic transition.
Single-Embryo Quantitative RT-PCR (q-PCR)
To further define the Oct4-regulated gene network, we selected
42 genes representing transcriptional, post-transcriptional and
signalling functions for q-PCR assays. We analyzed RNA from
single Oct4-MO-injected and control embryos and focused on
genes that were under-expressed in Oct4 knockdown. After
removing data related to 3 genes for which there were technical
difficulties, expression changes of 39 genes were appropriately
measured based on analysis using a linear model (See Methods S1
in Supplementary Online Materials). Of those, 34 or ,87%
showed altered expression levels in Oct4 knockdown in the
expected directions (Fig. 3 C and D), while 5 genes, including
Sox2, did not change (data not shown). 21 of the 34 genes, or
,62%, showed statistically significant differential expression by q-
PCR at p,0.05 or less, while injection of a control MO targeting
the human globin gene, which would not be present in the mouse
genome, did not alter expression of any of the genes assayed (data
not shown). Thus, we have proven that Oct4 directly or indirectly
regulates genes encoding a wide range of transcriptional and post-
transcriptional regulators at the 1- to 2-cell stages.
Quantitative Ranking of Candidate Genes in the Oct4-
Regulated Early Embryo Network
Our single-embryo data allowed us to go beyond simply
validating our gene chip data. Methods using samples comprised
of pooled cells or embryos, generate relative gene expression that
represents an average of all cells assayed, but they cannot discern
between genes that are consistently differentially regulated versus
those with a tendency towards stochastic changes; similarly, rare
outlier embryos expressing unique transcriptomes are not
recognized [31–33]. By analyzing quantitative expression data at
the single-embryo level, we were able to make this discrimination.
We presume genes whose relative expression is consistent amongst
single embryos have a higher likelihood to be essential nodes in a
gene regulatory network, which is expected to respond to
perturbations in a consistent and predictable manner. The gene
set was restricted to genes whose differential expression (repre-
sented by the difference in threshold cycles, DCT) DCT is greater
than expression differences amongst single embryos (represented
by standard error of the mean, s.e.m.). We propose a hierarchy in
the Oct4-regulated gene network in which 29 genes are ordered
based on their increasing s.e.m., or inter-embryo variation and
presumed decreasing biological significance in this network
(Fig. 4A). Interestingly, Rest, which has critical pluripotency
functions in ESCs [34], and Mta2, which encodes a member of
the Nanog and Oct4-associated deacetylase complex (NODE)
[35], were found to be the most tightly regulated by Oct4, based
on the small inter-embryo variation in their differential expression
in response to Oct4 knockdown. Taken together, we have identified
The 2-Cell Embryo Needs Oct4
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fashion.
Discussion
By exploiting our experimental strategy comprising MO-
mediated gene knockdown, global gene expression analysis, and
semi-quantitative gene expression analysis, simultaneous changes
in relative expression levels can be correlated for an entire network
of genes at the level of the single embryo to facilitate dissection of
the regulatory network. We envision that these Oct4-regulated
genes may serve as ‘‘portals’’ through which we can peer into and
deconstruct the dynamic gene network that directs development
and cell fate decisions, and that leads to the establishment of the
ESC gene network. Further, the lack of impact of Oct4 knockdown
on the expression levels of Cdx2, Nanog and Sox2 supports that the
role of Oct4 at the maternal-embryonic transition is distinct from
its well-established functions in ESCs, and suggests that other
Figure 4. Models of Oct4 function at the 1- to 2-cell stage. (A) Genes whose Absolute (DCT) (red) is greater than its s.e.m. (blue), are ordered
clockwise based on increasing s.e.m. (Log scale.) (B) Proposed regulation of various modules by Oct4 via transcriptional and post-transcriptional
mechanisms.
doi:10.1371/journal.pone.0004109.g004
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embryo.
Our data suggest that in the unique developmental context of
maternal-embryonic transition, concomitant with massive mRNA
degradation and dramatic reprogramming, Oct4 controls the
expression of many transcriptional regulators. Oct4 also maintains
the expression of many genes, such as Eif3c, Papola, Eif3b, Eif4e,
Rbm3 and Cpsf4, that are involved in the post-transcriptional
control. Through its influence on both the transcriptional and
post-transcriptional regulators, Oct4 can directly or indirectly
affect many essential processes, such as chromatin remodelling,
epigenetic regulation, apoptosis, cell cycle regulation, and
signalling, during early developmental program (Fig. 4B).
Given the importance of post-transcriptional regulation in the
transcriptionally silent mature oocyte, and the recapitulation of
some of the blastocyst and ESC Oct4 functions in the early
embryo–regulation of Fgf4 [10,36], Klf family member [37], Dppa5
[22] expression–the dual function of Oct4 in post-transcriptional
and transcriptional regulation at the maternal-embryonic transi-
tion suggests how stage-specific developmental requirements can
be fulfilled by a conserved pattern of gene networks. In fact, Oct4
may serve not only as a link between the germ cell and embryonic
developmental programs, but also as a switch from a post-
transcriptionally-regulated program to one that depends on the
transcriptional network. Future investigations of the precise
mechanisms by which Oct4 controls the early embryonic
transcriptional and post-transcriptional programs will uncover
important mechanisms of reprogramming in the early embryo,
and perhaps ESCs.
Materials and Methods
Embryo culture
All procedures involving animals were performed under our
active, Institutional Animal Care and Use Committee (IACUC)
protocol #8315 entitled ‘‘Developmental Regulation of the Mammalian
Embryo’’, which was approved by the Administrative Panel on
Laboratory Animal Care (APLAC) at Stanford University. 3–5
week old wild type F1 (C57BL66DBA/2) females (Charles River)
were superovulated by intraperitonial injections of 5 IU of
pregnant mare’s serum gonadotropin (Sigma) followed by 5 IU
of human chorionic gonadotropin (Sigma) 48 hours later, and
mated overnight with wild type males. Mice were sacrificed by
cervical dislocation 17 hours after hCG injection, and 1-cell
embryos were released from oviducts. Cumulus cells were
removed by hyaluronidase (Sigma) treatment and pipetting. Pre-
implantation embryos at the two pronuclei stage were recovered,
pooled from 3–6 females in M2 media (Chemicon International),
followed by immediate cytoplasmic microinjection and culture in
Human Tubal Fluid with 10% serum supplement (In-Vitro
Fertilization, Inc.) microdrops under mineral oil (Sigma) in mixed
gas (90% nitrogen, 5% oxygen, 5% carbon dioxide; Praxair) at
37uC, and cultured at ten embryos per 20 mL drop.
Microinjection of antisense morpholino oligonucleotides
25-nt, antisense morpholino oligonucleotides (MOs) that
specifically target the 59UTR or translational start site, or controls
mismatched at 5 nts were purchased from Gene Tools, LLC. (See
Supplementary Table 1 for sequence details). We had determined
0.6–0.75 mM to be the maximal concentration that would allow
normal rates of blastocyst development (data not shown). Hence,
unless otherwise specified, 5–10 pL of 0.75 mM Ccna2-MO
(0.60 mM for Oct4-MO) was injected into the cytoplasm of each
embryo on an inverted microscope (Olympus IX70) equipped with
hydraulic micromanipulation system (IM300 Microinjector, Nar-
ishige, Japan). 10 uninjected control embryos were used in each
experiment, which was performed at least three times. The mean
percentage and standard error of the mean (mean6s.e.m.) of
embryos progressing to, or arresting at, each developmental stage
were calculated, and statistical significance was determined by
calculating the p-value using 2-tailed Student’s t-test.
See Supporting Information for detailed materials and methods.
Control morpholino oligonucleotides
In each experiment, uninjected embryos and embryos injected
with a control morpholino were tested in parallel with Oct4-MO-
mediated knockdown. Overall, we used three different types of
control morpholinos, but only one type of control morpholino was
used in each experiment. 1) We used mismatch control
morpholinos in the embryo phenotype experiments to control
for the morpholino sequence, save 5 nucleotides. This mismatch
control would have controlled for the microinjection, the presence
of exogenous morpholino oligonucleotides in the cytoplasm, but
did not control for the biological effects of having morpholino-
bound transcripts in the cytoplasm. 2) In the gene chip
experiments, we targeted cyclin A2 transcript with specific
morpholinos. Here, the cyclin A2 experiments controlled for
microinjection, the presence of oligonucleotides in the cytoplasm,
and the biological effects of having morpholino-bound transcripts
in the cytoplasm. (Note that it was not possible to control for
having morpholino-bound Oct4 transcripts without actually
knocking down Oct4.) 3) In the single-embryo qPCR experiments,
we used a control morpholino that was designed to specifically
target the human globin (HG) gene promoter, which is not present
in the mouse genome. We had tested this HG morpholino when
establishing our methods and found that HG morpholino did not
affect blastocyst developmental rates. Importantly, genes that were
validated to be differentially-expressed between uninjected and
Oct4-MO-injected embryos were also confirmed to show no
differential expression between uninjected and HG-MO-injected
embryos. Therefore, the single-embryo qPCR experiments were
controlled for microinjection and the presence of morpholino
oligonucleotides in the cytoplasm.
Supporting Information
Methods S1 Detailed methods.
Found at: doi:10.1371/journal.pone.0004109.s001 (0.05 MB
DOC)
Figure S1 Limitation of conventional gene-targeting strategies
for the study of gene function during the maternal-embryonic
transition. Our overall goal is to address the specific functions of a
given gene product at the maternal-embryonic transition in order
to understand mechanisms that regulate mammalian embryo
development at the earliest stages. In wild type (+/2) embryos,
maternal transcripts are present before embryonic genome
activation (EGA), while maternal and embryonic transcripts are
present at maternal-embryonic transition stage, both resulting in
production of a normal gene product (A). In homozygous null
mutant (2/2) embryos generated from a mother that is
heterozygous (+/2) for the null mutation, persistent maternal
transcripts and/or proteins may ‘‘rescue’’ or delay the phenotype
onset (B). In contrast, homozygous null mutant embryos generated
from a homozygous mutant female, or a female with oocyte-
specific gene deletion, the observed defects may reflect oocyte
defects, rather than specific gene requirement in the early embryo
(C). Therefore, these strategies do not address the precise roles of
specific genes at the cusp of EGA or during EGA, when both
The 2-Cell Embryo Needs Oct4
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simultaneously. Cytoplasmic microinjection of antisense morpho-
lino oligonucleotides (MOs) into wild type embryo just at or before
EGA results in specific translational block of both maternal and
embryonic gene transcripts (D). Since MOs persist for at least a
few cycles of cell division, gene-specific translational block is
presumably effective until the morula-blastocyst stages (1–3). The
absence of gene product during these developmental stages would
reveal critical gene function and unmask early phenotypes that
may not be detectable in conventional gene-targeting strategies by
homologous recombination and transgenesis. While this model is
well established in other species (2, 4, 5), it shifts the paradigm
from investigating function of embryonic genes to that of gene
products regardless of their maternal or embryonic origin.
References. 1. Morcos PA (2007) Achieving targeted and
quantifiable alteration of mRNA splicing with Morpholino oligos.
Biochem Biophys Res Commun 358, 521–527. 2. Sumanas S &
Larson JD (2002) Morpholino phosphorodiamidate oligonucleo-
tides in zebrafish: a recipe for functional genomics? Brief Funct
Genomic Proteomic 1, 239–256. 3. Summerton J, et al. (1997)
Morpholino and phosphorothioate antisense oligomers compared
in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev
7, 63–70. 4. Imai KS, Levine M, Satoh N, & Satou Y (2006)
Regulatory blueprint for a chordate embryo. Science 312, 1183–
1187. 5. Yamada L, et al. (2003) Morpholino-based gene
knockdown screen of novel genes with developmental function
in Ciona intestinalis. Development 130, 6485–6495.
Found at: doi:10.1371/journal.pone.0004109.s002 (0.75 MB
DOC)
Figure S2 Experimental strategy. Embryos at the 2 pronuclei
(2PN) or 1-cell stage are collected from wild type matings, and
injected with an antisense morpholino oligomer (MO) that has
been designed to target a specific gene. MO binds to 59 UTR or
transcription start site and blocks translation by steric hindrance.
Microinjected embryos and uninjected control embryos are
cultured in vitro and observed for developmental phenotypes
such as fragmentation, or arrest at the 2-cell, 4-cell, multicell, or
morula stages. Theoretically, this strategy may uncover other
phenotypes such as asymmetrical division, but we have not
observed them in the genes that we have tested. If a gene-specific
MO produces the same phenotype consistently, while the
mismatch control MO allows normal development, then we
validate knockdown of the gene of interest by immunocytochem-
istry and/or immunoblotting. Mechanism of gene function is
further investigated by obtaining global gene expression profiles
from injected and control embryos at the mid-2-cell stage
(43 hours post-HCG). Candidate downstream genes are tested
for differential expression, and gene function in the early embryo.
It is expected that multiple iterations of this strategy to test
functions of different transcriptional regulators and their down-
stream targets will help to deconstruct the gene regulatory network
in the mouse embryo at the cusp of embryonic genome activation.
Found at: doi:10.1371/journal.pone.0004109.s003 (0.77 MB
DOC)
Figure S3 Oct4 expression in the mouse zygote by single
embryo RT-PCR.
Found at: doi:10.1371/journal.pone.0004109.s004 (0.11 MB TIF)
Figure S4 Decreased Oct4 expression was evident by the 4-cell
stage in Oct4-MO-injected embryos. Oct4 signal was absent in
embryos injected with Oct4-MO, but its nuclear localization was
present in uninjected and mismatch controls. Scale bar 40 mm.
Found at: doi:10.1371/journal.pone.0004109.s005 (10.94 MB
TIF)
Figure S5 Decreased Oct4 expression at the multicell stage in
Oct4-MO-injected embryos. Only 6.463.2% of Oct4-MO-
injected embryos showed nuclear Oct4 signal, while
88.9611.1% of Oct4-MM-injected embryos and 82.7610.9% of
uninjected control embryos showed unequivocal nuclear Oct4
expression at the multicell stage; p,0.05.
Found at: doi:10.1371/journal.pone.0004109.s006 (10.82 MB
TIF)
Figure S6 Oct4 knockdown could not be assessed by western
blot. Anti-Oct4 antibody detected specific Oct4 band in F9 mouse
embryonal carcinoma cell line, but not in the lane containing
pooled protein lysate from 57 mouse blastocysts. In contrast, the
band corresponding to RNA polymerase II (subunit A) was
detectable in both F9 cells and mouse blastocysts. This figure is
representative of experiments showing that 50–100 embryos at the
2-cell, multicell, and blastocyst stages did not have sufficient
amounts of Oct4 protein for detection by western blot. (PBS,
phosphate buffered saline)
Found at: doi:10.1371/journal.pone.0004109.s007 (0.57 MB TIF)
Figure S7 Confirmation of the requirement of Oct4 in early
embryo development by Oct4E4-MO, an antisense morpholino
that targets the splice site of exon 4 of Oct4. a, sites targeted by the
two morpholinos, Oct4-MO and Oct4E4-MO. Oct4-MO targets
the 25 nucleotides starting at the ATG start site, while Oct4E4-
MO targets the splice site at the intron (I)-exon (E) boundary of the
4th exon (E4). Removal of E4 is expected to result in a protein
product that lacks the DNA-binding and activation domains (1). b,
64.6619.9% of embryos injected with Oct4E4-MO, while none
that were injected with the mismatch control, Oct4E4-MM,
arrested at the 2-cell stage. c, Blastocyst development is severely
compromised after injection of Oct4E4-MO compared to the
mismatch control, Oct4E4-MM. Reference. 1. Morcos PA (2007)
Achieving targeted and quantifiable alteration of mRNA splicing
with Morpholino oligos. Biochem Biophys Res Commun 358,
521–527.
Found at: doi:10.1371/journal.pone.0004109.s008 (2.33 MB TIF)
Table S1 Antisense morpholino oligonucleotides target gene-
specific sequence in the 59UTR and/or start site.
Found at: doi:10.1371/journal.pone.0004109.s009 (0.06 MB
PDF)
Table S2 Summary of the number of embryos tested and the
number of experiments performed for each condition.
Found at: doi:10.1371/journal.pone.0004109.s010 (0.07 MB
PDF)
Table S3 Genes that have higher expression levels in Oct4-MO-
injected compared to uninjected embryos.
Found at: doi:10.1371/journal.pone.0004109.s011 (0.05 MB
XLS)
Table S4 Genes that have lower expression levels in Oct4-MO-
injected compared to uninjected embryos.
Found at: doi:10.1371/journal.pone.0004109.s012 (0.11 MB
XLS)
Table S5 Genes that have higher expression levels in Ccna2-
MO-injected compared to uninjected embryos.
Found at: doi:10.1371/journal.pone.0004109.s013 (0.03 MB
XLS)
Table S6 Genes that have lower expression levels in Ccna2-
MO-injected compared to uninjected embryos.
Found at: doi:10.1371/journal.pone.0004109.s014 (0.04 MB
XLS)
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binding sites based on genomic sequence analysis or mouse ESC
chromatin precipitation data*. *Data were compared to those
reported in: Zhou Q, Chipperfield H, Melton DA, & Wong WH
(2007) A gene regulatory network in mouse embryonic stem cells.
Proc Natl Acad Sci U S A 104, 16438–16443.
Found at: doi:10.1371/journal.pone.0004109.s015 (0.02 MB
PDF)
Table S8 Functional categories that were enriched in downreg-
ulated genes in the Ccna2 knockdown model.
Found at: doi:10.1371/journal.pone.0004109.s016 (0.03 MB
PDF)
Table S9 Functional categories that were enriched in upregu-
lated genes in the Ccna2 knockdown model.
Found at: doi:10.1371/journal.pone.0004109.s017 (0.01 MB
PDF)
Table S10 Functional categories that were enriched in down-
regulated genes in the Oct4 knockdown model.
Found at: doi:10.1371/journal.pone.0004109.s018 (0.02 MB
PDF)
Table S11 Functional categories that were enriched in upregu-
lated genes in the Oct4 knockdown model.
Found at: doi:10.1371/journal.pone.0004109.s019 (0.01 MB
PDF)
Table S12 Some candidate Oct4-regulated genes that function
in transcription, translation, RNA processing, chromatin remod-
eling, signaling, apoptosis and the cell cycle.
Found at: doi:10.1371/journal.pone.0004109.s020 (0.08 MB
PDF)
Table S13 Gene-specific primers and TaqmanH probes that
were used in q-PCR experiments.
Found at: doi:10.1371/journal.pone.0004109.s021 (0.04 MB
PDF)
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